Israel Englander’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Israel Englander’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,394	Closed	-$50.6K	–	6752
2023 Q4	$50.6K	Buy	+18,394	New	+$59.4K	﹤0.01%	5469
2023 Q2	–	Sell	-153,494	Closed	-$1.55M	–	6815
2023 Q1	$1.55M	Hold	153,494	–	–	﹤0.01%	3677
2022 Q4	$1.55M	Sell	153,494 -90,406	-37%	-$893K	﹤0.01%	3775
2022 Q3	$2.38M	Hold	243,900	–	–	﹤0.01%	3594
2022 Q2	$2.37M	Hold	243,900	–	–	﹤0.01%	3522
2022 Q1	$2.37M	Hold	243,900	–	–	﹤0.01%	3713
2021 Q4	$2.36M	Buy	243,900 +150,000	+160%	+$1.46M	﹤0.01%	3618
2021 Q3	$910K	Buy	+93,900	New	+$916K	﹤0.01%	4793

Other funds holding NKGN

Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $420M AUM 42.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TCM

Towneley Capital Management Laguna Hills, California $509M AUM 17.24% 1-Year Est. Return

Israel Englander's NKGN Position: Q1 2024 in Review

Israel Englander sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2024, closing a stake of 18,394 shares — an estimated $50.6K sold.

Israel Englander first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $2.38M in Q3 2022. 13 funds tracked by Wall St. Rank hold NKGN as of Q1 2024.

Israel Englander reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Israel Englander sold 18,394 NKGen Biotech, Inc. Common Stock shares in Q1 2024, an estimated $50.6K.
Israel Englander first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Israel Englander's NKGen Biotech, Inc. Common Stock position peaked at $2.38M in Q3 2022.
13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.